Cargando…

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

BACKGROUND: Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosylated to enhance antibody-dependent cellular cytotoxicity activity. We conducte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shitara, Kohei, Satoh, Taroh, Iwasa, Satoru, Yamaguchi, Kensei, Muro, Kei, Komatsu, Yoshito, Nishina, Tomohiro, Esaki, Taito, Hasegawa, Jun, Kakurai, Yasuyuki, Kamiyama, Emi, Nakata, Tomoko, Nakamura, Kota, Sakaki, Hayato, Hyodo, Ichinosuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694490/ https://www.ncbi.nlm.nih.gov/pubmed/31412935 http://dx.doi.org/10.1186/s40425-019-0679-9

Ejemplares similares

Novel anti-EPHA2 antibody, DS-8895a for cancer treatment
por: Hasegawa, Jun, et al.
Publicado: (2016)

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
por: Doi, Toshihiko, et al.
Publicado: (2018)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

A functional spleen contributes to afucosylated IgG in humans
por: Wojcik, Iwona, et al.
Publicado: (2021)

Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G
por: Arai, Hiroyuki, et al.
Publicado: (2021)

Afucosylated IgG responses in humans – structural clues to the regulation of humoral immunity
por: Oosterhoff, Janita J., et al.
Publicado: (2022)

Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies
por: Dong, Zhenyuan, et al.
Publicado: (2022)

Neutropenia in Cynomolgus Monkeys With Anti-Drug Antibodies Associated With Administration of Afucosylated Humanized Monoclonal Antibodies
por: Adedeji, Adeyemi O., et al.
Publicado: (2022)

Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)
por: Kajiwara, Takeshi, et al.
Publicado: (2023)

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G
por: Shitara, Kohei, et al.
Publicado: (2016)

BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2020)

Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells
por: Karampatzakis, Alexandros, et al.
Publicado: (2021)

Afucosylated Plasmodium falciparum-specific IgG is induced by infection but not by subunit vaccination
por: Larsen, Mads Delbo, et al.
Publicado: (2021)

Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity
por: Chakraborty, Saborni, et al.
Publicado: (2022)

Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG
por: Matsumoto, Yasuyuki, et al.
Publicado: (2023)

Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody
por: Gupta, Aaron, et al.
Publicado: (2023)

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
por: Kawakami, Hisato, et al.
Publicado: (2021)

Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
por: Huang, Sijia, et al.
Publicado: (2018)

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity
por: Larsen, Mads Delbo, et al.
Publicado: (2021)

Generation of FX (−/−) and Gmds (−/−) CHOZN host cell lines for the production of afucosylated therapeutic antibodies
por: Liu, Weiyi, et al.
Publicado: (2020)

Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice
por: Braster, Rens, et al.
Publicado: (2021)

Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern?
por: Teo, Andrew, et al.
Publicado: (2023)

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)
por: Okamoto, W., et al.
Publicado: (2022)

EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer
por: Nikas, Ilias, et al.
Publicado: (2022)

FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
por: Mishima, Hideyuki, et al.
Publicado: (2012)

Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study
por: Yoshino, Takayuki, et al.
Publicado: (2015)

Correction: Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern?
por: Teo, Andrew, et al.
Publicado: (2023)

EPHA2, EPHA4, and EPHA6 Expression in Uveal Melanomas: Searching for the Culprits of Neoplasia
por: Pergaris, Alexandros, et al.
Publicado: (2022)

First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose
por: Lin, Qingtang, et al.
Publicado: (2021)

A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
por: Nishina, Tomohiro, et al.
Publicado: (2013)

Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
por: Pereira, Natasha A., et al.
Publicado: (2018)

Assessment of the role of afucosylated glycoforms on the in vitro antibody-dependent phagocytosis activity of an antibody to Aβ aggregates
por: Kwiatkowski, Allyson, et al.
Publicado: (2020)

Afucosylation of HLA-specific IgG1 as a potential predictor of antibody pathogenicity in kidney transplantation
por: Bharadwaj, Pranay, et al.
Publicado: (2022)

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia
por: Pousse, Laurène, et al.
Publicado: (2023)

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2019)

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)
por: Kato, Ken, et al.
Publicado: (2018)

Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity
por: Hatfield, Grayson, et al.
Publicado: (2022)

EPHA2 Is Associated with Age-Related Cortical Cataract in Mice and Humans
por: Jun, Gyungah, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_92tkufrhc1pub5av27crgbpv1t